PAD is a leading cause of amputations in the U.S. But this serious circulatory condition often goes underdiagnosed and undertreated, so millions of Americans especially in the Black community don’t know they have it. Janssen’s Save Legs. Change Lives.™ aims to change that.
COMPASS open label extension study results support the long-term use of XARELTO plus aspirin for vascular protection in patients with chronic CAD and/or PAD
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial.